Sarepta Therapeutics (NasdaqGS:SRPT) experienced a share price increase of 10% over the last week, possibly affected by significant advancements in its gene therapy for Duchenne muscular dystrophy ...

Shares of Sarepta Therapeutics advanced after the company said it has received the go-ahead from U.K. regulators to keep dosing in a study of its Elevidys treatment for Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Sarepta Therapeutics shares were higher after J.P. Morgan reduced its December 2025 price target to $84 from $169 and maintained its overweight rating. The stock was up 4% to $39.55 Tuesday and is ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results , with sales up 80.2% year on year to $744.9 ...

Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

Data from the EMBARK trial suggest patients may have functional improvements taking the gene therapy between 8 and 9 years old.

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Learn how to optimize cold chain logistics for biotherapeutics in EMEA and overcome key challenges in delivery and regulation ...